Brawn Biotech Ltd (BRAWN) is currently trading at 21.49 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Brawn Biotech Ltd is a wholesale distributor of pharmaceutical and medical goods, offering a wide range of products including herbals, Ayurvedic, and critical care items. The company has international presence, marked by substantial growth in sales and profits due to its robust distribution network across global markets. Originally established as Brawn Pharmaceuticals in 1985, it rebranded to Brawn Biotech in 2010, symbolizing its evolution into a comprehensive healthcare entity. Brawn Biotech acts as a consignee agent for government hospitals and institutions, boosting its credibility and expanding its client base. With a focus on diverse product segments, including antibacterials and cardiovasculars, the company leverages its skilled team to maintain competitive market positioning.

Over the past 52 weeks, Brawn Biotech Ltd has traded between a low of ₹17.71 and a high of ₹24.37. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Brawn Biotech Ltd has a market capitalization of approximately 6.45. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Brawn Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 7.59 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6.45 Cr, Brawn Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Brawn Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Brawn Biotech Ltd is 7.59. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.